KORTUC Is Upgrading Radiotherapy From the Inside—And Giving Radiation-Resistant Cancer Patients a Second Chance
For decades, radiotherapy has been one of oncology’s most reliable workhorses. Precise. Predictable. Widely available.
And yet, for roughly 10% of cancer patients, it quietly fails.
Not because the machines aren’t advanced enough—but because biology gets in the way.
Hypoxic, enzyme-protected tumors create oxygen-starved microenvironments that blunt radiation’s lethal effect. These tumors don’t respond to standard doses, forcing clinicians into a corner: escalate radiation and risk toxicity, switch therapies, or accept limited control. It’s one of the least discussed—but most consequential—failure modes in modern cancer care.
KORTUC exists to fix that problem—without asking hospitals to buy a single new machine.
A Familiar Molecule, Reengineered for a Clinical Blind Spot
KORTUC is a clinical-stage oncology company developing a stabilized hydrogen peroxide–based radiosensitizer designed to make radiotherapy effective where it currently fails. Delivered via intratumoral injection, the therapy directly targets hypoxic, enzyme-protected solid tumors and restores the oxygen-rich conditions required for radiation to work.
Hydrogen peroxide is hardly exotic. What’s radical is how KORTUC has stabilized and regulated it into a clinically deployable radiosensitizer—one that integrates seamlessly into existing radiotherapy workflows.
“This is not about replacing radiotherapy,” says Kazu Matsuda, CEO of KORTUC. “It’s about correcting a biological mismatch. Radiotherapy fails some patients not because the technology is inadequate, but because the tumor environment disables it. KORTUC addresses that directly.”
The Upgrade Model, Not the Infrastructure Arms Race
Oncology innovation has increasingly become synonymous with capital expenditure—particle accelerators, proton therapy centers, next-generation imaging suites. These advances matter, but they also create access gaps, particularly outside elite academic centers.
KORTUC takes a different path.
Rather than introducing new hardware, it upgrades existing radiotherapy systems from within, allowing standard-dose radiation to penetrate resistant tumors more effectively. No new machines. No workflow disruption. No retraining bottlenecks.
For hospital administrators and radiation oncology departments, the value proposition is unusually clear: better outcomes for difficult cases without new capex.
In a healthcare environment defined by constrained budgets and workforce shortages, that distinction is decisive.
Proven in Patients, Not Just Preclinical Promise
Unlike many radiosensitization concepts that stall in early development, KORTUC is already proven in people.
More than 1,300 patients in Japan have been treated using KORTUC, generating a substantial real-world dataset demonstrating strong safety and efficacy. That evidence recently supported regulatory approval in the UK, marking a critical step in the company’s global expansion.
Early clinical findings indicate that KORTUC not only improves tumor control in resistant solid tumors, but may also enable lower total radiation doses, potentially reducing toxicity and side effects—an outcome with meaningful implications for patient quality of life.
For patients who have exhausted standard options, this is not marginal progress. It’s a material shift in what radiotherapy can deliver.
A Platform for the Next Wave of Combination Oncology
The impact of KORTUC extends beyond radiosensitization alone.
By altering the tumor microenvironment—specifically addressing hypoxia and enzyme-mediated resistance—the therapy may serve as a foundational platform for combination treatments, including radiotherapy–immunotherapy protocols that have historically struggled in oxygen-poor tumors.
As oncology increasingly moves toward precision combinations, KORTUC offers a way to make existing therapies work better together, rather than layering complexity on top of unresolved biological barriers.
Scaling What Already Works
Under Matsuda’s leadership, KORTUC is expanding from Japanese clinical use into global trials, working closely with regulators, payers, and radiation oncologists to ensure the therapy fits real-world practice—not just ideal lab conditions.
The company’s positioning is deliberately restrained. No miracle claims. No moonshot rhetoric. Just a targeted solution to a known and costly failure mode in standard cancer care.
For the subset of patients whose tumors resist radiation, KORTUC offers something quietly transformative:
a second chance—delivered through the same machines that failed them the first time, now upgraded from within.
About KORTUC
KORTUC is a clinical-stage oncology company developing stabilized hydrogen peroxide–based radiosensitizers for resistant solid tumors. With over 1,300 patients treated in Japan and recent UK regulatory approval, KORTUC is advancing global clinical trials to bring evidence-backed radiosensitization to cancer centers worldwide.
Learn more at https://kortuc.com/
